Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (82814)	2/14/2000 10:28:00 AM
From: Bob Biersack	Read Replies (1) \| Respond to of 120523

kendall...ASTM..on the move again!!

To: Jenna who wrote (82814)	2/14/2000 11:20:00 AM
From: Rose K	Read Replies (1) \| Respond to of 120523

EP #3 (2/14 announces earnings and stock split. Monday, February 14, 2000, 6:00 AM ET Pharmaceutical Company Announces a 2 for 1 Split EP #3 (2/14) announced that the Company's Board of Directors has approved a 2 for 1 split of the Company's common shares and ADRs. The Israel-based company has set a payable date of March 24th. The Company currently has approximately 62 million shares outstanding. Also announced was a 4th Quarter dividend of $0.11 per share (pre-split), payable to shareholders of record as of February 21st and payable on March 15th. The dividend and split announcements were made in conjunction with 4th quarter earnings, which came in at $0.64 per share (adjusted). First Call estimates had placed earnings at $0.62 per share. EP #3 (2/14) is Israel's largest pharmaceutical company. The Company develops, manufactures and markets branded and generic drugs, drug ingredients and medical disposables. The Company makes the branded drug Copaxone, which is used to treat multiple sclerosis. Over 80% of the Company's revenues are generated outside of Israel, mostly in the US and Europe. Shares of EP #3 (2/14) were first traded in the US in 1987. ADRs were issued at $9.25. The Company was originally founded in Israel in 1944. This is the second forward split for the Company. The first 2:1 split came in April 1993, while the stock was trading near $44.00. The stock has been surging since November 1999, trading from $50 to a recent high of $78.62 on January 19th. The 65-day ADV is 502,000 shares traded. The pharmaceutical companies have been under pressure since early December, but this stock is out-performing the sector.

To: Jenna who wrote (82814)	2/15/2000 12:43:00 AM
From: Jenna	Respond to of 120523

No glamour stock but could be good for more gains: GVA • Earnings out February 16 after the close • 2/4/00 Warburg Dillon Read Initiate coverage with a buy robust California market and excellent TEA-21 play, target $27 • 12/13/99 Ing Baring Furman Selz reiterates strong buy, 4Q EPS could beat expectations, announces good fit, low risk acquisition ************************************ • GVA was selected to the Forbes Platinum 400, a compilation of outstanding companies that meet a demanding series of requirements. The list looked for firms with sales greater than $750 million, strong revenue growth and return on capital ratios, and solid short-term and long-term earnings growth and cash flow per share. Home and nonresidential expenditures will slow down in '00 as interest rates begin to increase. However, companies in the highway and public works niche could flourish from a rise in government spending. The stock was selected to "The Forbes Platinum 400 Technicals**Cup & handle breakout and new 13 week high..on more than double average volume. A new upward trend is beginning and both trend setting indicators and oscillators point to a stock under accumulation: MACD has broken out, RSI is bullish as well. ADX has reached a 2 month high